Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
05/2003
05/20/2003US6566542 Such as 17-alpha-fluoro-11-beta-(4-(2-(1-piperidinyl) ethoxy) phenyl)-estra-1,3,5(10)-trien-3-ol for treatment of osteoporosis and cardiovascular protection; side effect reduction; provides alternative to estradiol
05/20/2003US6566390 Inhibiting a PTPase treating type 1 and 2 diabetes, insulin resistance and pathological obesity
05/20/2003US6566377 Have utility as, inter alia, hypoglycemic, and anti-obesity agents.
05/20/2003US6566367 Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines
05/20/2003US6566366 Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
05/20/2003US6566364 Linear or cyclic ureas
05/20/2003US6566362 Use as topical antibiotics
05/20/2003US6566353 Method of treating malignancy associated hypercalcemia using active vitamin D analogues
05/20/2003US6566352 Administering alpha -hydroxy-2-methylene-19-nor-pregnacalciferol compound for therapy of psoriasis
05/20/2003US6566340 Aryl-substituted propanolamine derivatives, their preparation, pharmaceuticals comprising them, and their use
05/20/2003US6566328 Administering to the patient a therapeutically effective amount of a polypeptide for therapy of patient in need of agonist effect of human growth hormone
05/20/2003US6566120 Contacting compactin with an agent derived from Actinomadura under conditions in which agent converts compactin to pravastatin; anticholesterol agent
05/20/2003US6566093 Alphavirus cDNA vectors
05/20/2003US6566066 Aquaporin-8 variant
05/20/2003US6565876 Carnitine and inositol phosphate-containing composition useful as dietary supplement or drug
05/20/2003US6565869 Administering genetic engineered polypeptide
05/20/2003US6565848 Cadherin-like asymmetry protein-1, and methods for its use
05/20/2003US6565829 Psychological disorders; central nervous system disorders
05/20/2003CA2088254C Treatment for hypercholesterolemia
05/20/2003CA2070524C Retinoids substituted by a dithiane cyclic and their use, process for the preparation of these compounds, cosmetic and pharmaceutical compositions containing them and therapeutical use of said compositions
05/15/2003WO2003040691A2 Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases
05/15/2003WO2003040392A2 Nucleic acids encoding very long chain fatty acid biosynthesis enzymes
05/15/2003WO2003040371A1 Novel g protein-coupled receptor protein and dna thereof
05/15/2003WO2003040358A1 Somatic cell derived embryonic stem cells and its differentiated cells
05/15/2003WO2003040329A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/15/2003WO2003040309A2 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
05/15/2003WO2003040296A2 Men protein, gst2, rab-rp1, csp, f-box protein lilina/fbl7, abc50, coronin, sec61 alpha, or vhappa1-1, or homologous proteins involved in the regulation of energy homeostasis
05/15/2003WO2003040174A2 Substituted amino ketone compounds
05/15/2003WO2003040144A2 Heterocyclic compound based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds
05/15/2003WO2003040138A1 Dimeric compounds and their use as anti-viral agents
05/15/2003WO2003040131A1 Aminopyrimidines and pyridines
05/15/2003WO2003040127A1 Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
05/15/2003WO2003040121A1 Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
05/15/2003WO2003040119A1 Angiogenesis inhibitors
05/15/2003WO2003040118A1 Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
05/15/2003WO2003040117A1 Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
05/15/2003WO2003040115A1 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase
05/15/2003WO2003040107A1 Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity
05/15/2003WO2003040101A1 Anthranilic acid amides and pharmaceutical use thereof
05/15/2003WO2003040099A1 Preparation of benzosuberonylpiperidine compounds
05/15/2003WO2003040098A1 Novel metalloproteinase inhibitors
05/15/2003WO2003040097A1 Nitrogenous compounds, production process, and method of use thereof
05/15/2003WO2003040084A1 Unsaturated 1-amino-alkylcyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists
05/15/2003WO2003040080A2 Lipoxin a4 analogs
05/15/2003WO2003039576A1 Psp-94: use for treatment of hypercalcemia and bone metastasis
05/15/2003WO2003039574A1 Endophilin homologous proteins involved in the regulation of energy homeostasis
05/15/2003WO2003039562A1 Composition and method
05/15/2003WO2003039548A1 Hydrazono-malonitriles
05/15/2003WO2003039547A1 Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake
05/15/2003WO2003039544A1 Naphtyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
05/15/2003WO2003039535A1 Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
05/15/2003WO2003039489A2 Endocrine pancreas differentiation of adipose tissue-derived stromal cells and uses thereof
05/15/2003WO2003039472A2 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
05/15/2003WO2003039452A2 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
05/15/2003WO2003039451A2 Thiazole pyridazinones as adenosine antagonists
05/15/2003WO2003039446A2 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
05/15/2003WO2003039434A2 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof
05/15/2003WO2003039260A2 Probiotic compositions
05/15/2003WO2003039231A2 Compounds and methods for treating transplant rejection
05/15/2003WO2002097032A3 Proteins associated with cell growth, differentiation, and death
05/15/2003WO2002094856A3 Gpe analogs and peptidomimetics
05/15/2003WO2002083926A3 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
05/15/2003WO2002064795A3 Putative human enzymes
05/15/2003WO2002057298A3 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
05/15/2003WO2002055108A9 Targeted modification of intracellular compounds
05/15/2003WO2002026781A9 Ige receptor antagonists
05/15/2003WO2002026717A8 Hydroxy acid integrin antagonists
05/15/2003WO2002000611A8 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists
05/15/2003WO2001079173A3 Enamine derivatives as cell adhesion molecules
05/15/2003US20030093821 For therapy of human subject diagnosed for predisposition for increased serum cholesterol or LDL cholesterol
05/15/2003US20030092917 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors
05/15/2003US20030092916 Process for the preparation of thiazolidinedione derivatives
05/15/2003US20030092908 Autoimmune diseases; rheumatic diseases; multiple sclerosis; inflammatory bowel disease; immunosuppressants
05/15/2003US20030092782 Adsorber of phosphorus
05/15/2003US20030092762 Anti-inflammatory nitro and thia-fatty acids
05/15/2003US20030092748 Benzenesulfonamide derivatives and their use as MEK inhibitors
05/15/2003US20030092744 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
05/15/2003US20030092736 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
05/15/2003US20030092735 Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome
05/15/2003US20030092732 Eating disorders; dietetics; antiinflammatory agents; autoimmune diseases
05/15/2003US20030092728 Antagonists of MCP-1 function and methods of use thereof
05/15/2003US20030092721 Antiinflammatory agents; rheumatic diseases
05/15/2003US20030092719 Methods and kits for treating depression or preventing deterioration of cognitive function
05/15/2003US20030092715 Aryl and biaryl compounds having MCH modulatory activity
05/15/2003US20030092714 Heterocyclic inhibitors of ERK2 and uses thereof
05/15/2003US20030092708 Anticholesterol agents; cardiovascular disorders; antilipemic agents
05/15/2003US20030092703 Caspase inhibitors and uses thereof
05/15/2003US20030092702 Antiinflammatory agents; autoimmune disease; autoimmune diseases
05/15/2003US20030092697 Antidiabetic, antilipemic agents; cardiovascular disorders; anticancer agents
05/15/2003US20030092687 5,6-Trans-2-alkylvitamin d derivatives
05/15/2003US20030092678 Muscle relaxants, controlling immunology, sexual disorders, rheumatic diseases
05/15/2003US20030092677 Glutamate receptor antagonists
05/15/2003US20030092631 IGF antagonist peptides
05/15/2003US20030092630 Amino acid side chain-modified substrates of the enzyme; obtaining locally limited inhibition; treating inflammation, psoriasis, periodontitis, allergies, arthritis, tumors or autoimmune diseases
05/15/2003US20030092601 Microcompetition and human disease
05/15/2003US20030092163 Probiotic bifidobacterium strains
05/15/2003US20030092059 Human antibodies that bind human TNFalpha
05/15/2003US20030092054 Protein complexes and assays for screening anti-cancer agents
05/15/2003US20030092044 Nucleotide sequences coding polypeptide for use in the treatment of apoptosis, inflammatory and autoimmune disorders
05/15/2003US20030091659 Plant extracts; active materials
1 ... 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 ... 1298